Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis-Reference-Cited by-同舟云学术

Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis

Published:2011-10 Issue:2 Volume:147 Page:306-319
ISSN:0092-8674
Container-title:Cell
language:en
Short-container-title:Cell

Author:

Grebien Florian,Hantschel Oliver,Wojcik John,Kaupe Ines,Kovacic Boris,Wyrzucki Arkadiusz M.,Gish Gerald D.,Cerny-Reiterer Sabine,Koide Akiko,Beug Hartmut,Pawson Tony,Valent Peter,Koide Shohei,Superti-Furga Giulio

Funder

University of Chicago

Canadian Institutes of Health Research

National Institutes of Health

European Molecular Biology Organization

U.S. Department of Energy

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference50 articles.

1. Controlling protein association and subcellular localization with a synthetic ligand that induces heterodimerization of proteins;Belshaw;Proc. Natl. Acad. Sci. USA,1996

2. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome;Daley;Science,1990

3. Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases;De Keersmaecker;Leukemia,2008

4. The development of imatinib as a therapeutic agent for chronic myeloid leukemia;Deininger;Blood,2005

5. Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation;Filippakopoulos;Cell,2008

Cited by 123 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structure‐Guided Drug Design Targeting Abl Kinase: How Structure and Regulation Can Assist in Designing New Drugs;ChemBioChem;2024-09-12

2. Cytosolic delivery of monobodies using the bacterial type III secretion system inhibits oncogenic BCR::ABL1 signaling;2024-08-05

3. Advancements and Future Prospects in Molecular Targeted and siRNA Therapies for Chronic Myeloid Leukemia;Biomolecules;2024-05-30

4. Development of mirror-image monobodies targeting the oncogenic BCR::ABL1 kinase;2024-04-26

5. Improving the pharmacokinetics, biodistribution and plasma stability of monobodies;Frontiers in Pharmacology;2024-04-04